TAK-653

Neurocrine Biosciences amended its agreement with Takeda to obtain exclusive worldwide rights to develop and commercialize osavampator for major depressive disorder (MDD), excluding Japan.

Neurocrine Biosciences has initiated a Phase 3 trial for osavampator as an adjunctive treatment for major depressive disorder (MDD).

Johnson & Johnson's Spravato, an esketamine-based nasal spray, marked the first new depression medication in decades, offering a more rapid treatment option than traditional SSRIs.

Neurocrine Biosciences' ERUDITE Phase 2 trial of luvadaxistat did not meet its primary endpoint for improving cognitive impairment in schizophrenia patients.